Home › NDC Lookup › RxCUI directory › RxCUI 2691328

Nemolizumab-ilto 30 MG Auto-Injector [Nemluvio] — RxCUI 2691328

RxNorm drug concept · Semantic branded drug
RxCUI 2691328 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2691328
Official nameNemolizumab-ilto 30 MG Auto-Injector [Nemluvio]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNemluvio 30 MG Auto-Injector
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)8,962 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Nemolizumab-ilto 30 MG Auto-Injector [Nemluvio] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nemolizumab-ilto 30 MG Auto-Injector [Nemluvio] RxCUI 2691328

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Nemolizumab 2691310
    • Nemolizumab-ilto 2691309
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nemluvio 2691317
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nemolizumab Auto-Injector 2691323
    • Nemolizumab-ilto Auto-Injector 2691324
    • Nemolizumab Injectable Product 2691312
    • Nemolizumab-ilto Injectable Product 2691314
    • Nemolizumab Auto-Injector [Nemluvio] 2691326
    • Nemolizumab-ilto Auto-Injector [Nemluvio] 2691327
    • Nemluvio Injectable Product 2691319
    • Auto-Injector 1649570
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nemolizumab-ilto 30 MG Auto-Injector SCD · 2691325
  • Nemolizumab-ilto 30 MG SCDC · 2691311
  • Nemolizumab Auto-Injector SCDF · 2691323
  • Nemolizumab-ilto Auto-Injector SCDFP · 2691324
  • Nemolizumab Injectable Product SCDG · 2691312
  • Nemolizumab-ilto Injectable Product SCDGP · 2691314

Brand-Name Concepts

  • Nemolizumab-ilto 30 MG [Nemluvio] SBDC · 2691318
  • Nemolizumab Auto-Injector [Nemluvio] SBDF · 2691326
  • Nemolizumab-ilto Auto-Injector [Nemluvio] SBDFP · 2691327
  • Nemluvio Injectable Product SBDG · 2691319
  • Nemluvio BN · 2691317

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2691328 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00299-6220-10 1 SYRINGE, GLASS in 1 CARTON (0299-6220-10) / 30 mg in 1 SY... NEMLUVIO Galderma Laboratories, L.P. 2024-08-13
00299-6220-15 1 SYRINGE in 1 CARTON (0299-6220-15) / 30 mg in 1 SYRINGE NEMLUVIO Galderma Laboratories, L.P. 2024-08-13
Observed labelers: Galderma Laboratories, L.P. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.